Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) FCF Margin (2021 - 2025)

Verrica Pharmaceuticals has reported FCF Margin over the past 5 years, most recently at 90.87% for Q4 2025.

  • Quarterly results put FCF Margin at 90.87% for Q4 2025, up 457890.0% from a year ago — trailing twelve months through Dec 2025 was 49.55% (up 49821.0% YoY), and the annual figure for FY2025 was 49.55%, up 75608.0%.
  • FCF Margin for Q4 2025 was 90.87% at Verrica Pharmaceuticals, down from 67.62% in the prior quarter.
  • Over the last five years, FCF Margin for VRCA hit a ceiling of 67.62% in Q3 2025 and a floor of 12435.14% in Q1 2023.
  • Median FCF Margin over the past 5 years was 509.98% (2023), compared with a mean of 2091.83%.
  • Biggest five-year swings in FCF Margin: crashed -1049894bps in 2023 and later surged 1191378bps in 2024.
  • Verrica Pharmaceuticals' FCF Margin stood at 92.47% in 2021, then crashed by -7884bps to 7382.35% in 2022, then surged by 90bps to 741.15% in 2023, then tumbled by -530bps to 4669.77% in 2024, then soared by 98bps to 90.87% in 2025.
  • The last three reported values for FCF Margin were 90.87% (Q4 2025), 67.62% (Q3 2025), and 78.91% (Q2 2025) per Business Quant data.